vs
Apellis Pharmaceuticals, Inc.（APLS）与HA Sustainable Infrastructure Capital, Inc.（HASI）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是HA Sustainable Infrastructure Capital, Inc.的1.7倍（$199.9M vs $114.8M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -46.8%，领先17.3%），HA Sustainable Infrastructure Capital, Inc.同比增速更快（13.3% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 4.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
HA可持续基础设施资本公司（HASI）是一家聚焦可持续基础设施领域的专业投资机构，业务覆盖可再生能源、能效提升、可持续地产及低碳公用事业板块，主要在北美市场运营，为合格绿色项目提供长期资本支持，为投资者创造稳定的经风险调整后回报。
APLS vs HASI — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $114.8M |
| 净利润 | $-59.0M | $-53.8M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -57.4% |
| 净利率 | -29.5% | -46.8% |
| 营收同比 | -5.9% | 13.3% |
| 净利润同比 | -62.2% | -176.7% |
| 每股收益（稀释后） | $-0.40 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $114.8M | ||
| Q3 25 | $458.6M | $103.1M | ||
| Q2 25 | $178.5M | $85.7M | ||
| Q1 25 | $166.8M | $96.9M | ||
| Q4 24 | $212.5M | $101.3M | ||
| Q3 24 | $196.8M | $82.0M | ||
| Q2 24 | $199.7M | $94.5M | ||
| Q1 24 | $172.3M | $105.8M |
| Q4 25 | $-59.0M | $-53.8M | ||
| Q3 25 | $215.7M | $83.3M | ||
| Q2 25 | $-42.2M | $98.4M | ||
| Q1 25 | $-92.2M | $56.6M | ||
| Q4 24 | $-36.4M | $70.1M | ||
| Q3 24 | $-57.4M | $-19.6M | ||
| Q2 24 | $-37.7M | $26.5M | ||
| Q1 24 | $-66.4M | $123.0M |
| Q4 25 | -25.6% | -57.4% | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | 84.7% | ||
| Q4 24 | -12.3% | 90.9% | ||
| Q3 24 | -24.0% | -32.1% | ||
| Q2 24 | -14.7% | 39.5% | ||
| Q1 24 | -36.0% | — |
| Q4 25 | -29.5% | -46.8% | ||
| Q3 25 | 47.0% | 80.8% | ||
| Q2 25 | -23.6% | 114.9% | ||
| Q1 25 | -55.3% | 58.4% | ||
| Q4 24 | -17.1% | 69.2% | ||
| Q3 24 | -29.2% | -23.9% | ||
| Q2 24 | -18.9% | 28.1% | ||
| Q1 24 | -38.5% | 116.3% |
| Q4 25 | $-0.40 | $-0.38 | ||
| Q3 25 | $1.67 | $0.61 | ||
| Q2 25 | $-0.33 | $0.74 | ||
| Q1 25 | $-0.74 | $0.44 | ||
| Q4 24 | $-0.30 | $0.58 | ||
| Q3 24 | $-0.46 | $-0.17 | ||
| Q2 24 | $-0.30 | $0.23 | ||
| Q1 24 | $-0.54 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $110.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $2.7B |
| 总资产 | $1.1B | $8.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $110.2M | ||
| Q3 25 | $479.2M | $301.8M | ||
| Q2 25 | $370.0M | $86.5M | ||
| Q1 25 | $358.4M | $67.4M | ||
| Q4 24 | $411.3M | $129.8M | ||
| Q3 24 | $396.9M | $44.1M | ||
| Q2 24 | $360.1M | $145.7M | ||
| Q1 24 | $325.9M | $61.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $2.7B | ||
| Q3 25 | $401.2M | $2.7B | ||
| Q2 25 | $156.3M | $2.6B | ||
| Q1 25 | $164.2M | $2.5B | ||
| Q4 24 | $228.5M | $2.4B | ||
| Q3 24 | $237.1M | $2.3B | ||
| Q2 24 | $264.3M | $2.3B | ||
| Q1 24 | $266.7M | $2.3B |
| Q4 25 | $1.1B | $8.2B | ||
| Q3 25 | $1.1B | $8.2B | ||
| Q2 25 | $821.4M | $7.6B | ||
| Q1 25 | $807.3M | $7.5B | ||
| Q4 24 | $885.1M | $7.1B | ||
| Q3 24 | $901.9M | $6.7B | ||
| Q2 24 | $904.5M | $6.7B | ||
| Q1 24 | $831.9M | $6.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $167.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $167.3M | ||
| Q3 25 | $108.5M | $-121.8M | ||
| Q2 25 | $4.4M | $79.6M | ||
| Q1 25 | $-53.4M | $-37.1M | ||
| Q4 24 | $19.4M | $5.9M | ||
| Q3 24 | $34.1M | $21.9M | ||
| Q2 24 | $-8.3M | $-24.8M | ||
| Q1 24 | $-133.0M | $20.9M |
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | -1.46× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | -0.66× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.94× | ||
| Q1 24 | — | 0.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HASI
暂无分部数据
